SK58198A3 - Treatment of traumatic brain injury - Google Patents

Treatment of traumatic brain injury Download PDF

Info

Publication number
SK58198A3
SK58198A3 SK581-98A SK58198A SK58198A3 SK 58198 A3 SK58198 A3 SK 58198A3 SK 58198 A SK58198 A SK 58198A SK 58198 A3 SK58198 A3 SK 58198A3
Authority
SK
Slovakia
Prior art keywords
tetrazol
tetrahydro
ethyl
methylpyridine
injury
Prior art date
Application number
SK581-98A
Other languages
English (en)
Slovak (sk)
Inventor
Brian R Pike
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SK58198A3 publication Critical patent/SK58198A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK581-98A 1995-11-06 1996-11-05 Treatment of traumatic brain injury SK58198A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (1)

Publication Number Publication Date
SK58198A3 true SK58198A3 (en) 1998-10-07

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
SK581-98A SK58198A3 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Country Status (18)

Country Link
EP (1) EP0866706A1 (cs)
JP (1) JPH11514654A (cs)
KR (1) KR19990067353A (cs)
AU (1) AU706594B2 (cs)
BG (1) BG63150B1 (cs)
BR (1) BR9611396A (cs)
CA (1) CA2234824A1 (cs)
CZ (1) CZ287441B6 (cs)
EA (1) EA000531B1 (cs)
HU (1) HUP9901051A2 (cs)
IS (1) IS4726A (cs)
NO (1) NO982036L (cs)
NZ (1) NZ321546A (cs)
PL (1) PL326490A1 (cs)
SK (1) SK58198A3 (cs)
TR (1) TR199800801T2 (cs)
WO (1) WO1997017074A1 (cs)
ZA (1) ZA969320B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
CA2234824A1 (en) 1997-05-15
ZA969320B (en) 1997-05-30
JPH11514654A (ja) 1999-12-14
EA000531B1 (ru) 1999-10-28
PL326490A1 (en) 1998-09-28
BR9611396A (pt) 1999-07-13
EP0866706A1 (en) 1998-09-30
EA199800434A1 (ru) 1998-10-29
AU706594B2 (en) 1999-06-17
NZ321546A (en) 2000-12-22
CZ138998A3 (cs) 1998-10-14
HUP9901051A2 (hu) 2000-03-28
NO982036D0 (no) 1998-05-05
WO1997017074A1 (en) 1997-05-15
MX9803432A (es) 1998-09-30
TR199800801T2 (xx) 1998-08-21
NO982036L (no) 1998-06-25
IS4726A (is) 1998-04-27
CZ287441B6 (en) 2000-11-15
BG63150B1 (bg) 2001-05-31
AU7490096A (en) 1997-05-29
KR19990067353A (ko) 1999-08-16
BG102480A (en) 1999-01-29

Similar Documents

Publication Publication Date Title
DE69631134T2 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
JP2020128384A (ja) 医薬溶液、調製方法及び治療的使用
EP2040548B1 (en) Method for the treatment of neurological disorders by enhancing the activity of beta -glucocerebrosidase
DE69718731T2 (de) Kombinationstherapie für die Behandlung von Psychosen
DE3686622T2 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
DE69834508T2 (de) Apoptoseinhibitoren
DE69932154T2 (de) Verwendung von n-substituirten-1,5-dideoxy-1,5-imino-d-glucitolen zur behandlung von hepatitis infektionen
JP2018519358A (ja) 神経変性疾患を処置する方法
SK4862000A3 (en) The use of 5-ht3 receptor antagonists
US6297262B1 (en) Treatment of schizophrenia and psychosis
SK58198A3 (en) Treatment of traumatic brain injury
DE69432474T2 (de) Verwendung von 2-(2aklylphenylamino)oxazolinen und-thiazolinen zur herstellung eines medikaments mit alpha 2 adrenergener wirkung
KR20020001850A (ko) 기분장애, 적응장애 또는 혼재성 불안우울증의 치료 또는예방에 사용되는 의약의 제조를 위한 사레듀턴트 및 그의제약상 허용되는 염의 용도
EP0278467B1 (de) Verwendung von Oxochinazolinderivaten bei der Behandlung von Hyperurikämie
US4305942A (en) Xanthine oxidase inhibitor and therapeutic treatment using same
EP3849976B1 (en) A gaba a receptor ligand
AU649953B2 (en) Tetrahydroisoquinolinylcarbamates of 1,2,3,3A,8,8A-hexahydro-1,3A,8-trimethylpyrrolo(2,3-B)indole
US20070191400A1 (en) Pharmaceutical compositions comprising anti-inflammatory quinazolinecarboxamide derivatives
DE3904795C2 (de) Pharmazeutisches Präparat und dessen Verwendung
US20230165852A1 (en) Method for treating central nervous system disorders using dopamine d3 partial agonists
CA2541045A1 (en) A descarbonylethoxyloratadine containing pharmaceutical composition
CA2533492A1 (en) Use of 3,7-diazabicyclo[3,3,1]nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
MXPA98003432A (en) Treatment of traumat cerebral damage
US20050054667A1 (en) Method of treating or inhibiting anti-arrhythmic events in male human patients
CN117396202A (zh) 给药方案